6934
HCmed Innovations Co., Ltd. designs, develops, manufactures, and sells mesh nebulizers to deliver liquid medications into the respiratory airways in the United States, Europe and Asia. The company's products include Pulmogine, a vibrating mesh nebulizer to nebulize a range of liquid medications to treat respiratory diseases and their symptoms in children and adults; and AdheResp, a breath-actuate… Read more
6934 (6934) - Total Liabilities
Latest total liabilities as of September 2025: NT$87.87 Million TWD
Based on the latest financial reports, 6934 (6934) has total liabilities worth NT$87.87 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
6934 - Total Liabilities Trend (2020–2024)
This chart illustrates how 6934's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
6934 Competitors by Total Liabilities
The table below lists competitors of 6934 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Huili Building Materials Co Ltd
SHG:900939
|
China | $35.67 Million |
|
Equatorial Pará Distribuidora de Energia S.A
SA:EQPA3
|
Brazil | R$17.07 Billion |
|
Annovis Bio Inc
NYSE:ANVS
|
USA | $4.03 Million |
|
Teleste Oyj
HE:TLT1V
|
Finland | €65.98 Million |
|
Ta-Yuan Cogeneration Co Ltd
TWO:8931
|
Taiwan | NT$3.03 Billion |
|
ASICLAND
KQ:445090
|
Korea | ₩96.24 Billion |
|
Icares Medicus Inc
TWO:6612
|
Taiwan | NT$1.25 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down 6934's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 6934's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 6934 (2020–2024)
The table below shows the annual total liabilities of 6934 from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$37.48 Million | -23.63% |
| 2023-12-31 | NT$49.07 Million | +91.30% |
| 2022-12-31 | NT$25.65 Million | -90.19% |
| 2021-12-31 | NT$261.47 Million | -1.53% |
| 2020-12-31 | NT$265.54 Million | -- |